{"doi":"10.1093/infdis/jiab315","title":"Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants","abstract":"BACKGROUND: The fusion (F) glycoprotein of respiratory syncytial virus (RSV) represents the major neutralizing antigen, and antibodies against the pre-F conformation have the most potent neutralizing activity. This study aimed to assess the correlation between maternal antibody titers against the pre-F, post-F, and G glycoproteins and the child's risk of developing severe RSV bronchiolitis early in infancy. METHODS: We identified previously healthy term infants <3 months of age hospitalized with RSV bronchiolitis from December 2015 to March 2016. We measured IgG antibody titers to pre-F, post-F, and G proteins in maternal sera obtained at 9-12 weeks of pregnancy of these hospitalized infants' mothers (n = 94) and compared them with serum antibody titers of control pregnant mothers (n = 130) whose children were not hospitalized. RESULTS: All maternal samples (n = 224) had detectable pre-F antibodies. Pre-F antibody titers were significantly lower in mothers whose infants were hospitalized with RSV bronchiolitis compared with those mothers whose infants were not hospitalized (23.9 [range (or antibody titer range), 1.4-273.7] µg/L vs 30.6 [XXX, 3.4-220.0] µg/L; P = .0026). There were no significant differences in maternal post-F and G antibody titers between hospitalized and nonhospitalized infants. CONCLUSIONS: Our findings indicate that maternal pre-F antibodies are fundamental for providing immune protection to the infant.","journal":"The Journal of Infectious Diseases","year":2021,"id":165375,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":36,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9626,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":688910,"name":"Tea Nieminen","orcid":"0000-0003-2157-4567","position":1,"is_corresponding":false},{"id":32980,"name":"Asunción Mejías","orcid":"0000-0002-5983-8006","position":2,"is_corresponding":false},{"id":689942,"name":"Cristina Capella Gonzalez","orcid":null,"position":3,"is_corresponding":false},{"id":688911,"name":"Fang Ye","orcid":"0000-0003-3505-3500","position":4,"is_corresponding":false},{"id":300254,"name":"Sara Mertz","orcid":null,"position":5,"is_corresponding":false},{"id":236197,"name":"Mark E. Peeples","orcid":"0000-0002-4582-317X","position":6,"is_corresponding":false},{"id":33005,"name":"Octavio Ramilo","orcid":"0000-0002-0565-5239","position":7,"is_corresponding":false},{"id":689943,"name":"Harri Saxén","orcid":null,"position":8,"is_corresponding":false},{"id":689941,"name":"Karoliina Koivisto","orcid":null,"position":0,"is_corresponding":true}],"reference_count":49,"raw_metadata":null,"created_at":"2026-07-18T23:45:40.838485Z","pmid":"34129040","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}